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Abstract
Background: Natural killer (NK) cells are members of the innate immune system. Their unique properties, including recognition of viral 
infected and tumor cells without major histocompatibility complex (MHC) restriction or prior sensitization, make them a suitable choice 
for immunotherapy. Low numbers of NK cells in circulating blood is the most important obstacle for this goal.
Objectives: The aim of this study was to make an optimum in vitro condition to proliferate and differentiate cord blood (CB)-NK cell 
progenitors to mature NK cells, which can be used for cell therapy.
Materials and Methods: In our study, CB-Mononuclear Cells’ (MNCs) CD3+ lymphocytes were positive depleted using immunomagnetic 
microbeads. This CD3-depleted (CD3-dep) CB - MNCs compartment was used for in vitro expansion with or without a layer of amnion 
membrane mesenchymal stem cells (MSCs) in combination with cytokines that are essential for NK cells expansion (IL-2, IL-3, IL-15, and 
FLT3 ligand). The expansion period lasted for one week. On day seven, immunophenotype and fold expansion of differentiated cells were 
measured.
Results: Combination of cytokines and MSC layer yielded significant fold expansion in comparison with cytokines without feeder 
conditions (day 7: 5.2 ± 1.12 and 2 ± 0.78, respectively, P < 0.05). CD3-/CD56+ cells percentage increased during the culture period in MSCs/
with cytokine and cytokine/without feeder, respectively (day 0: 4.4 ± 0.42% and day 7: 22.9 ± 3.6% and 13.9 ± 1.92 % for MSC/with cytokine and 
cytokine without feeder, respectively).
Conclusions: Our results suggested that CB-NK cells progenitors could proliferate and differentiate on feeder layer of amnion membrane 
MSCs in combination with specific cytokines to produce NK cells for immunotherapy.
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1. Background
In the past decade, many studies have focused on how 
the immune system recognizes and reacts to tumor cells. 
Furthermore, mechanisms by which cancer cells tolerate 
immune system attacks have been discovered (1).
Treating patients with malignancy using immune cells 
has been a major issue in the recent years (2). The im-
mune system is made up of several cell types that have 
specific function and unique properties. Innate immune 
system is composed of granulocyte, monocyte-macro-
phage, natural killer, and dendritic cells, whereas T and 
B lymphocyte are compartments of the adaptive portion. 
Natural killer (NK) cells are a member of lymphocyte-like 
cells recognized by expression of CD56 and the absence 
of CD3. These cells comprise about 15% of circulating 
lymphocytes. Resting NK cells circulate in blood yet after 
activation, these cells can migrate to most tissues that 
include pathogen-infected or malignant cells (3). These 
cells can lyse viral infected and tumor cells without ma-
jor histocompatibility complex restriction or prior sensi-
tization (4, 5). Natural killer cells can also rapidly prime 
other immune cells through production of soluble fac-
tors, cytokines, or chemokines that induce anti-microbial 
effects (3). These unique phenomena make NK cells a suit-
able choice for manipulation and use in cell therapy.
Natural Killer cell transplantation efficacy and safety 
have been approved in metastatic melanoma, renal cell 
carcinoma, refractory Hodgkin lymphoma, and acute 
myeloid lymphoma (6).
Low numbers of NK cells in the circulating blood is the 
most important obstacle for immunotherapy. In vivo NK 
cell expansion by means of such cytokine administration 
may be restricted by competition with host lymphocytes 
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or by suppression through recipient regulatory T-cells 
(T- regulatory) or myeloid suppressor cells (7). The use 
of autologous NK cell therapy has little efficacy in most 
cases, partially due to down regulation of NK cells kill-
ing mechanisms that occur with recognition of self-MHC 
class I on tumor cells (8-10).
To obtain a large number of proper cells, some authors 
have described in vitro proliferation methods useful for 
clinical scale NK cell production from hematopoietic 
stem cells (7). Umbilical cord blood is one of the most 
abundant sources of non-embryonic stem cells (11). These 
stem cells, which are at the intermediate stage between 
embryonic and adult stem cells, have a higher prolifera-
tion capacity and longer telomeres when compared to 
other somatic stem cells (12).
2. Objectives
The aim of this study was to initiate an in vitro method 
of producing the maximum number of NK cells with a dif-
ferentiated phenotype on a stromal co-culture system in 
the presence of NK cell differentiation inducible cytokines.
3. Materials and Methods
3.1. Separation of Amnion Membrane Mesenchy-mal Stem Cells (MSCs)
For this study, placenta tissue was obtained from normal 
full term Caesarian delivery and transported to the cell cul-
ture lab in sterile conditions. The amnion membrane was 
separated mechanically and washed with phosphate buf-
fer solution (PBS) three times and cut in to small pieces. It 
was then placed in collagenase type IV solution (1 mg/mL) 
(Sigma, Germany) for four hours at 37°C, in the presence of 
5% CO2 in a shaker incubator. Collagenase solution contain-
ing separated cells and undigested fragments was passed 
through a seventy-micrometer filter. Passed cells were 
washed with PBS and cultured in Dulbecco’s modified ea-
gle medium (DMEM) with low glucose (Sigma, Germany) 
supplemented with 10% fetal bovine serum (FBS) (Thermo 
Fisher, USA), penicillin 100 IU/mL and Streptomycin 100 µg/
mL (Thermo Fisher, USA) in a T75 cell culture flask.
Under these conditions MSCs attach to the plastic sur-
face of the flask. After 24 hours of incubation at 37°C with 
5% CO2, non-MSC cells were removed through washing 
with PBS, and MSCs were allowed to proliferate for five 
more days. When cells reached 90% confluence, the flasks 
were treated with 0.25% Tyrpsin-EDTA (Sigma, Germany) 
to harvest MSCs. Floating cells were transferred to new 
flasks or used as feeder in assays at passage three to five.
3.2. Collection and Preparation of CD3-Depleted Cord Blood Mononuclear Cells
Cord blood was obtained in citrate phosphate dextrose 
(CPD) blood bag units. mononuclear cells (MNCs) were 
separated by density gradient centrifugation using Fi-
coll-hypaque (Lymphodex, Inno-Train, Germany).
After washing with PBS and depleting platelets, cells 
were counted and CD3+ lymphocyte were removed by im-
munomagnetic bead selection using the CD3-MicroBeads 
MACS system (Miltenyi Biotec, Germany), according to 
the kit’s instructions. Eluted cells considered as CD3- de-
pleted cord blood MNCs included NK cells CD3-/CD56+ 
progenitors, and were used for NK expansion. These pop-
ulations contained less than 1% CD3+ cells.
3.3. Natural Killer Cell Differentiation
Amnion membrane derived MSCs were plated 6 × 104 cell/
well in 24 well tissue plates in low glucose-DMEM contain-
ing 10% FBS, penicillin 100 IU/mL, and streptomycin 100 µg/
mL. After 24 hours and after reaching 90% confluence, in or-
der to stop proliferation of MSCs, wells were washed with 
PBS and filled with DMEM containing 100 µg/mL mitomy-
cin only two hours before being used as a feeder. Next, the 
wells were washed two more times with PBS and once with 
StemSpan media (Stemcell Technology, USA) to remove mi-
tomycin from the cells environment. CD3-depleted cells 
cultured in 300×103 cells/ wells were included MSCs and 
cytokines (IL-2 250 IU/mL , IL-15 10 ng/mL, IL-3 10 ng/mL, 
and FLT-3 ligand 10 ng/mL (Miltenyi Biotech, Germany)) 
and cytokine without MSCs feeder respectively. Cells were 
cultured for one week and the media was changed every 
two days. At day seven, cells were harvested from the wells, 
washed, and counted with trypan blue (Thermo Fisher, 
USA) and used for immunophenotyping assays.
3.4. Identification of Surface Antigens With Flow Cytometry
CD16, CD56, and CD3 were investigated on the cells be-
fore and after differentiation using specific anti-bodies 
including Fluorescein isothiocyanate-conjugated CD16, 
Phycoerythrin-conjugated CD56, and PerCP-conjugated 
CD3 (BD Bioscience, USA), respectively. Flow cytometry 
analysis was done with a Partec flow cytometer (Sysmex, 
Japan) using the Flowmax software.
For statistical analysis, t-student test was used and the 
results were significant if P was < 0.05.
4. Results
4.1. Natural Killer Cell Differentiation
Natural Killer cells were characterized as CD3-/CD56+ 
cells. Expression of these markers in fresh CD3-dep cells 
and at day seven of differentiation in co-culture with MSC 
feeder and cytokines cocktail was investigated by flow 
cytometry. Fresh CD3-dep from cord blood included 4.4 
± 0.42% of NK cells whereas CD3-dep that expanded with 
MSCs and cytokines and cytokines without feeder con-
tained 22.9 ± 3.6% and 13.9 ± 1.92% , respectively on day 
seven of differentiation (Table 1).
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Table 1. CD3-/CD56+ Percentage During Expansion in Different Conditions
MSC Feeder, W/cyto Feeder Free, W/cyto
Onset of co -culture 4.4 ± 0.42 4.4 ± 0.42
Day 7 22.9 ± 3.6 13.9 ± 1.92
Abbreviation: W/cyto, with cytokine.
5. Discussion
The aim of this study was to introduce an optimum con-
dition for NK cell precursor population to produce NK 
cells, which can be used for cell therapy. Cord blood NK 
cells are preferred to T-cells for immunotherapy because 
of their ability to recognize malignant or infected cells 
without MHC molecule antigen introduction. These cells 
have also shown fewer and of course more slight GvHD 
incidence (13).
Due to the inadequate number of NK cells in cord blood, 
their clinical application has been limited. In order to 
solve this problem, we tried to introduce a method for ef-
ficient expansion of NK cell progenitors.
In previous studies, in vitro expansion of NK cell precur-
sors using various cytokines such as IL-2, IL-15, and FLT-3 was 
conducted (14, 15). Similarly, useful effect of transfected cells 
with NK co-stimulator genes in co-culture with NK precur-
sors in their expansion has been reported previously (16).
Membrane mesenchymal stem cells are popular for 
their immune alteration effect via cell-cell interaction 
and cytokine secretion (17).
In the present study, the expansion of NK cells using a 
feeder layer of allogenic mitomycin-treated MSCs derived 
from amnion membranes was investigated. To reduce 
the risk of excess proliferation of T cells in culture, CD3+ 
lymphocytes were separated from CB-MNCs by the immu-
nomagnetic separation method. The obtained CD3- cells 
were then put on feeder cells with or without combina-
tion of cytokines.
Under this condition, on day seven, an average of 5.2 ± 
1.12 and 2 ± 0.78 folds of expansion of NK cells in the cul-
ture containing MSCs with cytokines and cytokines only 
was achieved, respectively without T cells contamination 
(P < 0.05) (Figure 1).
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Figure 1. Folds Change During Expansion Under Different Conditions (w/
cyto, with cytokine)
In this protocol, all CD3- cells such as monocytes were 
entered to the co-culture. These cells were actually con-
tributed to the NK cells proliferation by cytokine secre-
tion. This finding was consistent with the observation of 
Gada et al. (18), who reported that highly pure CD56+ cells 
from CB-MNCs had a poor expansion (only 4.5 fold) com-
pared to CB-MNCs that were CD3-depleted only (14.5-fold).
In summary, our study showed that MSCs feeder incor-
poration with NK cells lineage specific cytokines could 
enhance fold expansion making it a suitable method to 
gain competent NK cells for immunotherapy.
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